Mandaviya seeks Japanese pharma collaboration, touts growth opportunities in domestic market
New Delhi: The union health minister Mansukh Mandaviya on Monday sought Japanese collaboration on research and innovation in emerging technologies like precision medicine, cell and gene therapy, biological products, and on the utilization of digital tools.
While interacting with representatives of Japanese pharma companies and members of the Japan Pharmaceutical Manufacturers Association (JPMA) at the Indian Embassy in Tokyo, Mandaviya said, “Such collaboration on research and innovation would help enhance the domestic availability and affordability of these innovative therapeutic options”.
He encouraged Japanese companies to take advantage of growing opportunities in the Indian market.
“The pharmaceutical industry in India has been attracting a lot of investment from foreign companies and seeing partnerships and collaborations. This has opened up exciting opportunities for global pharmaceutical companies to enter the Indian market. The new Production Link Incentive (PLI) schemes have also encouraged manufacturers to produce drugs in India, with the aim of supplying them to the global market,” said Mandaviya.
Mandaviya, who is on his visit to Japan to attend G7 meeting, stated that India is recognized as a global pharmaceutical hub, with its industry playing a pivotal role in improving health outcomes worldwide by serving as a dependable supplier of affordable and high-quality drugs.
“India has played a significant role in enhancing global accessibility by providing approximately 60% of the global vaccine supply and 20-22% of generic exports. In the battle against the COVID-19 pandemic, India has supplied essential drugs to around 185 countries,” he said adding that the Indian pharmaceutical industry has primarily focused on manufacturing generic medicines, exporting bulk drugs, and supplying active pharmaceutical ingredients.
“The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030″, he said.
He further informed that “3 Bulk Drug Parks are coming up to create a robust ecosystem for pharmaceutical manufacturing. To promote research and development in the pharmaceutical sector, the Indian government has established six National Institutes of Pharmaceutical Education and Research and designated them as ‘Institute of National Importance. In 2019, the launch of the New Drugs and Clinical Trial Rules further contributed to the growth of the clinical trial sector, with many choosing India as a site for global clinical trials”.
He informed that globally, research and innovation in the field of bio-pharmaceuticals have become key drivers for growth in the life sciences sector, particularly with the rising prevalence of biologics and biosimilars and highlighted that “In India, the bio-pharmaceutical sector has achieved an impressive 5-year Compound Annual Growth Rate (CAGR) of 50% and is projected to continue thriving”.
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint.
Download The Mint News App to get Daily Market Updates.
More
Less
No Byline Policy
Editorial Guidelines
Corrections Policy
Source